Alkem Laboratories Limited — Q4 FY25
Alkem Laboratories reported Q4 FY25 revenue of INR 3,144 crore, up 7.1% YoY, driven by domestic growth of 8.1% and international growth of 7.2%.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Full-year EBITDA margin guidance maintained at 19%
Despite 21.6% margin in 9M, Q4 is seasonally weak with higher R&D spend (5 filings), so full-year margin expected around 19%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Domestic business to grow in line with IPM (~7%) for FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
US business expected to be flat YoY in Q4
Improved from -22% in Q2 to -7% in Q3; supply normalization should lead to neutral growth by Q4.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1